Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Heart, Lung, and Blood Institute (NHLBI)
Asthma is a major public health problem that is associated with significant morbidity and mortality. Patients at increased risk for asthma decompensations include those with severe asthma that is refractory to therapy, as well as patients with poorly controlled disease due to inadequate treatment. The aim of this exploratory specimen procurement protocol is to develop a non-invasive method for the detection of asthma-specific biomarkers in exhaled breath condensates (EBC) utilizing a novel collection device that was engineered at the Johns Hopkins University Applied Physics Laboratory. Biomarkers in EBC will be identified by mass spectroscopy. We propose that the identification of biomarkers in EBC that correlate with airway inflammation and disease activity may be used to guide therapy and prevent exacerbations in asthmatic patients.
Age
18–75
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Patients will be between 18 and 75 years of age, male or female, with a diagnosis of asthma for at least one year.
Oxygen saturation on room air greater than or equal to 92 percent.
Research volunteers will be between 18 and 75 years of age, male or female.
Oxygen saturation on room air greater than or equal to 92 percent.
You may not be if
Diagnosis of a pulmonary disorder other than asthma (for example: chronic bronchitis, emphysema, cystic fibrosis, bronchiectasis, sarcoidosis, HIV-related lymphocytic airway inflammation).
Cigarette smoking within the past 3 months or a prior history of greater than 10 cumulative pack-years.
History of coronary artery disease.
Reversible Airflow Obstruction (increase in FEV (1) by 12 percent and 200 cc after inhaled beta 2-agonist)
Clareo Health | Biomarkers in Exhaled Breath From Asthmatic Patients
